KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Shares Issued (2020 - 2024)

AbCellera Biologics filings provide 4 years of Shares Issued readings, the most recent being $227000.0 for Q3 2024.

  • Quarterly Shares Issued fell 11.33% to $227000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Sep 2024, down 36.99% year-over-year, with the annual reading at $4.6 million for FY2021, 99.12% down from the prior year.
  • Shares Issued hit $227000.0 in Q3 2024 for AbCellera Biologics, down from $461000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $521.9 million in Q4 2020 and bottomed at $124000.0 in Q1 2020.
  • Average Shares Issued over 4 years is $37.9 million, with a median of $475500.0 recorded in 2023.
  • Peak annual rise in Shares Issued hit 1246.46% in 2021, while the deepest fall reached 99.65% in 2021.
  • AbCellera Biologics' Shares Issued stood at $521.9 million in 2020, then tumbled by 99.65% to $1.8 million in 2021, then tumbled by 86.04% to $256000.0 in 2023, then fell by 11.33% to $227000.0 in 2024.
  • Per Business Quant, the three most recent readings for ABCL's Shares Issued are $227000.0 (Q3 2024), $461000.0 (Q2 2024), and $892000.0 (Q1 2024).